Interpharm Holdings Stock Market Outlook
| IPAH Stock | USD 0.0041 0.00 0.00% |
Interpharm Holdings' sentiment score summarizes the balance between positive and negative signals in recent news and social media and is used here as a behavioral input rather than as a trading instruction. Around 56% of recent sentiment around Interpharm Holdings has been mildly defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for Interpharm Holdings close to neutral at this time.
Investor Comfort Level
PanicConfidence
44 · Impartial
Elasticity to Hype and News Sentiment
Tracking Interpharm Holdings mixed news sentiment (50%) is particularly informative when headlines and price behavior start diverging. Whether that tone sustains depends on how the next batch of company disclosures compares with the current media narrative.
Given a 90-day horizon, with an above-average risk tolerance, the model output for Interpharm Holdings is 'Strong Sell'. The Interpharm Holdings buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for Interpharm Holdings.
Interpharm |
Run Interpharm Holdings Outlook Model
The Interpharm model signal complements the current analyst consensus on Interpharm Holdings. Macroaxis holds no financial interest in Interpharm Holdings or in any other asset this module covers.
How This Model Works
The recommendation output for Interpharm Holdings is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Hold
Not Rated
For the selected horizon, Interpharm Holdings yields Return On Equity TTM of -1.17, Return On Asset TTM of -0.19, and Profit Margin TTM of -0.42, which produce a balanced but non-directional signal.The model output for Interpharm Holdings integrates risk-adjusted performance, valuation signals, and the current expert consensus into a single quantitative reading. For additional context on this micro-cap stock, review the full set of Interpharm Holdings reported fundamentals, including short ratio ttm, trailing beta, and the relationship between the current ratio ttm and working capital ttm. As Interpharm Holdings appears to be a penny stock, its price to sales ttm numbers are an important reference point for this model output.
Recent Events and Market Context
The events below reflect recent headlines associated with Interpharm Holdings. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Key Drivers of Volatility and Market Exposure
Interpharm Holdings is exposed to both systematic and unsystematic risk. Systematic risk reflects broader stock market movements, while company or sector-specific developments represent nonmarket drivers. Diversification may reduce specific risk, but market exposure remains. Beta and standard deviation help quantify volatility. Interpharm Holdings (IPAH) operates as a public company with notable key financial metrics data points.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Fundamentals Vs Peers
Interpharm Holdings' fundamentals tested against peer averages expose where the stock leads, lags, or diverges from its group. Revenue growth, margin structure, and return on capital at Interpharm Holdings are tested against the same metrics at comparable stocks.
| Better Than Average | Worse Than Average | Compare Interpharm Holdings to competition |
| Fundamentals | Interpharm Holdings | Peer Average |
| Return On Equity TTM | -1.17 | -0.31 |
| Return On Asset TTM | -0.19 | -0.14 |
| Profit Margin TTM | -0.42 | -1.27 |
| Operating Margin TTM | -0.24 | -5.51 |
| Current Valuation | 2.07 M | 16.62 billion |
| Number Of Shares Shorted | 1.13 M | 4.71 million |
| Price To Sales TTM | 0.03 X | 11.42 X |
| Revenue TTM | 75.59 M | 9.43 billion |
| Gross Profit TTM | 12 M | 27.38 billion |
| EBITDA TTM | -16.57 M | 3.9 billion |
| Net Income TTM | -14.06 M | 570.98 million |
| Cash And Equivalents TTM | 41 K | 2.7 billion |
| Total Debt TTM | 12.06 M | 5.32 billion |
| Debt To Equity TTM | 3.43 % | 48.70 % |
| Current Ratio TTM | 0.62 X | 2.16 X |
| Book Value Per Share TTM | -0.08 X | 1,931 |
| Cash Flow From Operations TTM | -14.11 M | 971.22 million |
| Short Ratio TTM | 289.66 X | 4.00 X |
| Earnings Per Share | -0.09 X | 3.12 X |
| Number Of Employees | 670 | 18,840 |
| Trailing Beta | -102.04 | -0.15 |
| Market Capitalization TTM | 2.07 M | 19.03 billion |
| Total Asset TTM | 74.37 M | 29.47 billion |
| Working Capital TTM | -16.64 M | 1.48 billion |
| Current Asset TTM | 27.38 M | 9.34 billion |
| Current Liabilities TTM | 44.01 M | 7.9 billion |
| Net Asset | 74.37 M | N/A |
Market Momentum
Strength signals for Interpharm Holdings show whether demand and trading pressure are supporting or weakening the current setup. Interpharm Holdings strength signals are most actionable when combined with support-resistance levels and the implied volatility curve.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0041 | |||
| Day Typical Price | 0.0041 |
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Interpharm Holdings reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Interpharm Holdings include ROE of -117.07%, market cap of 2.07 million. 
Interpharm Holdings data is compiled from periodic company reporting and market reference feeds and standardized for comparability. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.